Novo Nordisk said on Monday it has filed a lawsuit against U.S. telehealth firm Hims & Hers over alleged patent infringement.
The Danish drugmaker claims Hims has infringed its patents by selling unapproved, compounded drugs linked to its proprietary treatments.
The company is also seeking financial damages related to the claimed infringement, according to its statement.
The lawsuit highlights rising tensions around compounded medicines offered through digital health platforms.
Such products have drawn increased scrutiny as demand surges for weight-loss and metabolic treatments.
The case could set an important precedent for patent enforcement in the fast-growing U.S. telehealth market.
